TNF-alpha stimulates alveolar liquid clearance during intestinal ischemia-reperfusion in rats.
Intestinal ischemia-reperfusion commonly occurs in critically ill patients and may lead to the development of remote organ injury, frequently involving the lungs. In the present study, alveolar liquid clearance was studied in ventilated, anesthetized rats subjected to 45 min of intestinal ischemia followed by 3 h of reperfusion. An isosmolar 5% albumin solution was instilled into the lungs, and alveolar liquid clearance was measured from the increase in alveolar protein concentration as water was reabsorbed over 45 min. Intestinal ischemia-reperfusion resulted in a 76% increase in alveolar liquid clearance compared with the control value (P < 0.05). The stimulated alveolar liquid clearance seen after intestinal ischemia-reperfusion was not inhibited by propranolol, indicating stimulation through a noncatecholamine-dependent pathway. Intestinal ischemia-reperfusion did not result in increased intracellular cAMP levels. Amiloride inhibited similar fractions in animals subjected to ischemia-reperfusion and control animals. Administration of a neutralizing polyclonal anti-tumor necrosis factor-alpha antibody before induction of intestinal ischemia completely inhibited the increased alveolar liquid clearance observed after intestinal ischemia-reperfusion. In conclusion, our results suggest that intestinal ischemia-reperfusion in rats leads to stimulation of alveolar liquid clearance and that this stimulation is mediated, at least in part, by a tumor necrosis factor-alpha-dependent mechanism.
Börjesson
A
A
Department of Surgery, Lund University Hospital, SE-221 85 Lund, Sweden.
Norlin
A
A
Wang
X
X
Andersson
R
R
Folkesson
H G
HG
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000584:Amiloride / Q000494:pharmacology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D001834:Body Water / Q000378:metabolism; D002199:Capillary Permeability / Q000187:drug effects; D000242:Cyclic AMP / Q000096:biosynthesis; D004730:Endothelium, Vascular / Q000378:metabolism; D007422:Intestines / Q000098:blood supply*; D007511:Ischemia / Q000378:metabolism*; D008168:Lung / Q000378:metabolism; D008297:Male; D011433:Propranolol / Q000494:pharmacology; D011506:Proteins / Q000378:metabolism; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D015427:Reperfusion Injury / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000276:immunology / Q000494:pharmacology*
D000319:Adrenergic beta-Antagonists; D000911:Antibodies, Monoclonal; D011506:Proteins; D014409:Tumor Necrosis Factor-alpha; D000584:Amiloride; D011433:Propranolol; D000242:Cyclic AMP